The integration of artificial intelligence (or AI) into global companies’ operations continues to accelerate. The biotechnology industry’s highly complex operations are especially well suited to AI applications. For perspective, since 2023 the drug discovery and treatment repurposing sectors have seen a steady flow of AI-based innovations.
Leen Kawas, Ph. D. is well acquainted with the drug discovery and development cycle. As Propel Bio Partners’ Managing General Partner, Dr. Kawas oversees the biotech venture capital firm’s partnerships with start-up and early-stage biotech companies. Dr. Kawas welcomes pitches from innovative biotech entrepreneurs, especially female and minority candidates.
Read the full article here: https://disruptinsider.com/articles/dr-leen-kawas-discusses-ais-integration-into-the-drug-development-cycle/
Comments